Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | MPL | P40238 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | FEN1 | P39748 | 5/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387952 | 0.92 | L3MBTL1 (0.42) | HSD11B1MPLCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2386650 | 0.86 | MPL (0.41) | HSD11B1MPLCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2386527 | 0.84 | ADORA2A (0.43) | HSD11B1MPLCYP1A2CYP2C19ALOX5AP | |
| SCHEMBL2307176 | 0.83 | MPL (0.41) | HSD11B1MPLCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2386528 | 0.82 | L3MBTL1 (0.46) | HSD11B1MPLCYP1A2CYP2C19ALOX5AP | |
| SCHEMBL2388021 | 0.82 | MPL (0.40) | HSD11B1MPLCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2388300 | 0.82 | MEN1 (0.38) | HSD11B1MPLCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1894636 | 0.82 | CTSA (0.45) | HSD11B1MPLCTSAALOX5APFEN1 | |
| SCHEMBL2388782 | 0.81 | MPL (0.42) | HSD11B1MPLCYP1A2CYP2C19ALOX5AP | |
| SCHEMBL1891905 | 0.81 | HSD11B1 (0.50) | HSD11B1MPLCTSAALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230485-A1 | 6-PHENYL-PYRIMIDIN-4-YL-(PHENYLAMINE OR PHENOXY) DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-09-22 | — | — | US | claimed |
| US-20110230485-A1 | 6-PHENYL-PYRIMIDIN-4-YL-(PHENYLAMINE OR PHENOXY) DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230485-A1 | 6-PHENYL-PYRIMIDIN-4-YL-(PHENYLAMINE OR PHENOXY) DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA5, CHRNA6, CHRNA7 | HSD11B1 4016/4885MPL 1319/4885CYP1A2 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.